The association between high protein intake and risk of IBD was investigated in the EPIC-IBD cohort, which is embedded in the main EPIC study (n=521,000). In the presented analysis, 413,593 participants were included.
After a mean follow-up of 16 years, 595 incident cases of IBD were identified: 418 cases of UC and 177 cases of Crohn’s disease (CD). There was no association between total protein intake and risk of IBD (adjusted HR for the fourth versus vs first quartile 1.25; 95% CI 0.89–1.77; P-trend=0.33). The association between the calibrated continuous variable of animal protein intake and IBD risk was significant, however (aHR per 10 g/day 1.10; 95% CI 1.00–1.21). There was no association between vegetable protein intake and IBD risk. Meat consumption and IBD risk were found to be associated (aHR for the fourth vs first quartile 1.37; 95% CI 1.02–1.82; P-trend=0.003). The same was true for red meat consumption and IBD risk (aHR for the fourth vs the first quartile 1.41; 95% CI 1.03–1.92; P-trend=0.006). There was an association between total meat, as well as red meat, and risk of UC. No association was found between animal proteins and risk of CD.
- Dong C, et al. ECCO-IBD 2020, OP17.
Posted on
Previous Article
« CD exclusion diet corrects dysbiosis Next Article
Role of immune cells in intestinal fibrosis »
« CD exclusion diet corrects dysbiosis Next Article
Role of immune cells in intestinal fibrosis »
Table of Contents: ECCO 2020
Featured articles
Gut Microbiome as Treatment Target
Response to faecal microbiota transplantation in UC
Bioactives produced by gut bacteria to modulate immune response
Big Data Analysis
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Experimental Therapies: Study Results
AMT-101: an oral human IL-10 fusion protein
Phase 2 results of first-in-class TL1A inhibitor
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Short- and Long-Term Treatment Results
Infliximab discontinuation increases relapse risk
Tofacitinib ‘real-world’ effectiveness in active UC
Subcutaneous ustekinumab as maintenance therapy in UC
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Specific Therapeutic Strategies
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Top-down infliximab superior to step-up in children with CD
High versus standard adalimumab in active UC
Head-to-Head Comparison of Treatments
Vedolizumab and anti-TNF therapies: a real-world comparison
Cancer Risk
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Miscellaneous Topics
Resolution of mucosal inflammation has dramatic effect
PICaSSO validated in real-life study
Re-inducing inflammation in organoids from UC patients
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
CD exclusion diet corrects dysbiosis
Related Articles
April 14, 2020
Vedolizumab treatment persistence and safety
April 14, 2020
Increased incidence of colorectal cancer and death in CD
April 14, 2020
Association between meat consumption and IBD risk
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com